These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12241648)

  • 1. Ovarian cancer chemotherapy: carboplatin as standard.
    Tattersall MN
    Lancet; 2002 Aug; 360(9332):500-1. PubMed ID: 12241648
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
    Hoogland H; Blijham G; Bron H; Eekhout A; van Geuns H; Haest J; Huiskes H; Kornman J; de Koning Gans H; Lalisang F
    Prog Clin Biol Res; 1985; 201():213-5. PubMed ID: 3841592
    [No Abstract]   [Full Text] [Related]  

  • 4. [Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer].
    Hernádi Z; Juhász B; Póka R; Mahunka I; Lampé L
    Orv Hetil; 1987 Nov; 128(47):2457-61. PubMed ID: 3320851
    [No Abstract]   [Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
    Pignata S; Lauraine EP; du Bois A; Pisano C
    Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum alone for chemotherapy for ovarian cancer?
    Johnston C
    Lancet; 1998 Nov; 352(9140):1567-8. PubMed ID: 9843097
    [No Abstract]   [Full Text] [Related]  

  • 8. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early ovarian cancer and the icon trials.
    Ghersi D; Parmar MK; Stewart LA; Marsoni S; Williams CJ
    Eur J Cancer; 1992; 28A(6-7):1297. PubMed ID: 1627401
    [No Abstract]   [Full Text] [Related]  

  • 10. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy in the management of ovarian germ cell malignancies.
    Schwartz PE
    Obstet Gynecol; 1984 Oct; 64(4):564-72. PubMed ID: 6207473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
    Sugiyama T
    Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120
    [No Abstract]   [Full Text] [Related]  

  • 13. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian epithelial tumors of low malignant potential.
    Chien RT; Rettenmaier MA; Micha JP; DiSaia PJ
    Surg Gynecol Obstet; 1989 Aug; 169(2):143-6. PubMed ID: 2756462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer: what is poor prognosis disease?
    Cohen MH
    J Clin Oncol; 1990 Jul; 8(7):1287-8. PubMed ID: 2113572
    [No Abstract]   [Full Text] [Related]  

  • 16. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
    Chylak V; Krusić J; Kolarić K
    Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
    [No Abstract]   [Full Text] [Related]  

  • 17. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
    Cure H; Dauplat J; Cholet P
    Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils JA
    Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carboplatin/epirubicin/prednimustine (Sterecyt) as an adjuvant chemotherapy combination in ovarian cancer treated by radical surgery].
    Pickel H
    Gynakol Rundsch; 1989; 29 Suppl 2():357-8. PubMed ID: 2693256
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status of chemotherapy for ovarian carcinoma.
    ten Bokkel Huinink WW
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):583-5. PubMed ID: 3133217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.